GeneDx Holdings (WGS) Research & Development (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Research & Development data on file, last reported at $19.8 million in Q1 2026.

• Research & Development for Q1 2026 came in at $19.8 million, up 57.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $79.3 million (up 69.59% YoY), and the FY2025 annual result was $72.0 million, up 57.53% from the prior year.
• Research & Development eased to $19.8 million in Q1 2026 per WGS's latest filing, from $24.5 million in the prior quarter.
• Over five years, Research & Development peaked at $27.2 million in Q2 2022 and troughed at $10.9 million in Q2 2024.
• A 5-year average of $16.6 million and a median of $14.6 million in 2023 frame the typical range for Research & Development.
• On a YoY basis, Research & Development climbed as much as 127.31% in 2022 and fell as far as 59.88% in 2022.
• A 5-year view of Research & Development shows it stood at $24.4 million in 2022, then sank by 49.73% to $12.2 million in 2023, then fell by 5.39% to $11.6 million in 2024, then surged by 111.78% to $24.5 million in 2025, then declined by 19.3% to $19.8 million in 2026.
• Business Quant data shows WGS's Research & Development at $19.8 million in Q1 2026, $24.5 million in Q4 2025, and $19.8 million in Q3 2025.